美国卵巢癌不同诊疗阶段的费用分析
该回顾性队列研究利用2015年1月1日至2020年12月31日诊断的7913例卵巢癌患者医保索赔数据,估算诊断后5年内不同阶段的费用。费用与年龄和地理区域相关,与种族/民族无关联。
要点
- 年龄与各阶段费用存在统计学显著关联:较年轻患者相比,较年长患者在延续治疗阶段费用更高、临终阶段费用更低。
- 各诊疗阶段均观察到地理区域费用差异,未发现费用与种族/民族存在关联。
核心结论
- 卵巢癌诊疗费用高昂,且因诊疗阶段、年龄类别和地理区域而异。
- 随着更有效但更昂贵的治疗方案出现并可能带来生存获益,需要在癌症诊疗全过程中采取可持续的干预措施以降低卵巢癌诊疗费用。
研究设计与样本
- 回顾性队列研究,纳入2015年1月1日至2020年12月31日诊断的卵巢癌患者7913例。
- 数据来源为Optum去标识化Clinformatics Data Mart数据库,涵盖全国商业保险和Medicare受益人的住院、门诊和处方索赔。
- 费用按起始治疗阶段(最初6个月)、延续治疗阶段(起始与临终治疗之间的时期)和临终治疗阶段(最后6个月)计算,以2021年美元金额报告。
- 费用按年龄、种族/民族和地理区域分层;因费用数据呈偏态,均值费用经对数转换后建模,采用普通最小二乘回归调整年龄、种族/民族和地理区域。
主要发现
- 年龄与各诊疗阶段费用存在统计学显著关联:与较年轻患者相比,较年长患者在延续治疗阶段费用更高,在临终治疗阶段费用更低。
- 无论诊疗阶段如何,均观察到卵巢癌诊疗费用的地理差异。
- 在本队列中,费用与种族/民族无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian cancer is associated with delayed diagnosis and poor survival; thus, interest is high in identifying predictive and prognostic biomarkers and novel therapeutic agents. Although the costs of ovarian cancer care are likely to increase as newer, more effective, but more expensive treatment regimens become available, information on the current costs of care for ovarian cancer-across the care continuum from diagnosis to the end of life-are lacking. OBJECTIVE: This study aimed to estimate real-world mean and median costs of ovarian cancer care within the first 5 years after diagnosis by patients' phase of care, age, race/ethnicity, and geographic region. STUDY DESIGN: We performed a retrospective cohort study of ovarian cancer patients diagnosed between January 1, 2015 and December 31, 2020. We used claims data from Optum's deidentified Clinformatics Data Mart database, which includes inpatient, outpatient, and prescription claims for commercial insurance and Medicare beneficiaries nationwide. Cost of ovarian cancer care were calculated for the start of care (ie, the first 6 months), continuing care (ie, period between the initial and end-of-life care), and end-of-life care (ie, the last 6 months) phases and reported in 2021 U.S. dollar amounts. Ovarian cancer care costs were stratified by age, race/ethnicity, and geographic region. Due to the skewed nature of cost data, the mean cost data were log-transformed for modeling. Ordinary least-squares regression was conducted on the log costs, adjusting for patient categorical age, race/ethnicity, and geographic region. RESULTS: A total of 7913 patients were included in the analysis. The mean cost per year for ovarian cancer care was >$200,000 during the start of care, between $26,000 and $88,000 during the continuing care phase, and >$129,000 during the end-of-life care phase. There were statistically significant associations between age and costs during each phase of care. Compared to younger patients, older patients incurred higher costs during the continuing care phase and lower costs during the end-of-life care phase. Geographic differences in the costs of ovarian cancer care were also noted regardless of the phase of care. There were no associations between cost and race/ethnicity in our cohort. CONCLUSION: Ovarian cancer care costs are substantial and vary by the phase of care, age category, and geographic region. As more effective but expensive treatment options for ovarian cancer become available with potential survival benefit, sustainable interventions to reduce the cost of care for ovarian cancer will be needed throughout the cancer care continuum.
引用
- Adjei NN, Haas AM, Sun CC, et al. Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol. 2024. PMID: 39159781. doi:10.1016/j.ajog.2024.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。